RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. The purpose of this study was to evaluate th...

Full description

Bibliographic Details
Main Authors: John J. Tentler, Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young B. Lee, Andrew Eisen, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, Todd M. Pitts, Roberta Pelanda, S. Gail Eckhardt, Jennifer R. Diamond
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
RX-5902
Triple-negative breast cancer
p68
β-Catenin
PD-1 inhibitor
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-020-07500-1

Internet

http://link.springer.com/article/10.1186/s12885-020-07500-1

Similar Items